

## Our Mission

Our mission is to transform healthcare by developing innovative therapies that meet the needs of patients suffering from undertreated medical conditions, improving their quality of life.

## Our Vision

Our vision is to empower lives by providing innovative therapies that target undertreated medical needs and improve health outcomes globally.

## Our Values

**Empathy:** We understand and prioritize the experiences of patients and their families.

**Responsibility:** We take accountability for our actions and their impact on society and the environment.

**Diversity:** We embrace diverse perspectives to foster creativity and drive innovation.

## About Us

BioXL is at the forefront of developing biopharma solutions for undertreated medical needs through innovative research and advanced technology. Our approach encompasses the full spectrum of drug development, from discovery to clinical stage, ensuring that each project evolves into an independent company for further development and commercialization. Based in Israel, BioXL operates as a hub of innovation and is proud to be a member of The ARC Center for Digital Innovation at Sheba Medical Center. Located in Sderot's technological hub, we are surrounded by innovative startups and are in close proximity to Ben Gurion University, the Weizmann Institute of Science, and Kiryat Weizmann Science Park. We aim to play a meaningful role in developing Sderot's biotech ecosystem.





## Our Offering

At BioXL, we offer two investment options to meet diverse interests. The first allows you to invest directly in BioXL, participate in our mission, and benefit from our advancements in groundbreaking therapies. The second option lets you invest in individual projects that will become separate entities, each with its own unique name, focusing on specific innovations. Our diverse portfolio includes projects across various therapeutic fields, all at different development stages.

### CeaseCancer

#### A universal anti-cancer drug, alternative to chemotherapy

CeaseCancer targets Pancreatic Ductal Adenocarcinoma (PDAC), the most common and lethal form of pancreatic cancer, and Triple-Negative Breast Cancer (TNBC). This therapy leverages the natural tumor-suppressing properties of the Klotho protein, providing a safer and more effective alternative to existing treatments, either as a monotherapy or in combination with chemotherapy.

### CancerPredict

#### Diagnostic Test for Improved Cancer Prognosis

CancerPredict enhances breast cancer risk prediction and outcomes using digital pathology and AI. It improves screening and quality of life. Stage: Pre-clinical development.

### AMP-Bio

#### Antibiotic Resistant Bacteria Treatment

AMP-Bio is developing antimicrobial peptides to combat antibiotic-resistant bacteria. It aims to treat infections while minimizing impacts on patients' microbiomes. Stage: Discovery.

### NES Pharma

#### Neurodegenerative Diseases Treatment

NES Pharma is developing a combination drug to slow Alzheimer's progression and delay cognitive decline in mild cognitive impairment (MCI) patients. Stage: Discovery.

### Marathon

#### Longevity Treatment

Marathon is developing a vehicle for safe mitochondria replacement therapy (MRT) to enhance longevity and quality of life. Stage: Discovery.





## Who We Are: Key Management

BioXL has brought together scientific experts and successful business leaders who share a passion for innovating. Our team has vast experience in biological sciences and in managing business platforms.



### **CEO: Meir Azulay (MSc)**

An expert in biopharmaceutical manufacturing with experience at Merck-Serono, and a co-founder of several startups.




### **CTO, Portfolio Manager: Avraham Laban (PhD)**

Brings vast expertise in drug development and biochemical analysis, with academic roles at MIT and Harvard.



### **Business Development Director: Ouri Fischel (PhD, MBA)**

Experienced in drug discovery and investment banking, with a history of successful funding initiatives.



### **Chairman: Stephen Simes (BSc, MBA)**

A veteran biopharma executive with extensive experience in raising capital and managing public companies.



### **Market Development, Asia: ToonLee Ng (BSc Hons, MBA)**

An entrepreneur whose experience and knowledge enable her to seek partners for joint ventures with BioXL.



## Who We Are: Advisory Board



### **Prof. Ido Wolf (MD, PhD)**

A pioneer in cancer research and the inventor of CeaseCancer, Oncology Division Head at Tel Aviv Sourasky Medical Center.



### **Tamar Rubinek (PhD)**

Leading cancer researcher, Head of Oncology Division Research Lab at Tel Aviv Medical Center.



### **Mazal Dahan (PhD)**

Formulation expert with significant experience in biotech and pharma sectors.



### **Prof. Ouriel Faktor (PhD, MBA)**

A diagnostic development expert with extensive experience in the biopharmaceutical industry.

**BioXL is committed to transforming the landscape of healthcare through our innovative products and research, addressing some of the most pressing medical needs today.**

### **Connect With Us: Meir Azulay, CEO**

Email: [meir.biom@gmail.com](mailto:meir.biom@gmail.com)

Cel: +972-54-953-6396

Address: Ahavat Israel 9, Sderot, Israel

BioXL is a member of  
ARC Innovation at  
Sheba Medical Center

